Published in Biochem Pharmacol on December 16, 2013
Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Mol Cancer (2015) 1.01
Activation of β2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells. Cell Signal (2015) 0.79
Selective GPR55 antagonism reduces chemoresistance in cancer cells. Pharmacol Res (2016) 0.75
Concurrent activation of β2-adrenergic receptor and blockage of GPR55 disrupts pro-oncogenic signaling in glioma cells. Cell Signal (2017) 0.75
In Vitro Antiproliferative Activity of Extracts of Carlina acaulis subsp. caulescens and Carlina acanthifolia subsp. utzka. Front Pharmacol (2017) 0.75
Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science (1999) 7.57
The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci (2002) 5.04
The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol (2007) 4.22
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol (1995) 2.95
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther (1996) 2.90
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem (1999) 2.73
G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol (2009) 2.60
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol (2005) 2.42
Reaching out for signals: filopodia sense EGF and respond by directed retrograde transport of activated receptors. J Cell Biol (2005) 2.26
Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun (2007) 2.18
Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods (2008) 2.10
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem (2007) 1.77
Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci (1995) 1.68
Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A (2008) 1.67
beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem (2000) 1.67
Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep (2005) 1.65
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci (2008) 1.48
The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol (2011) 1.46
GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol (2010) 1.39
The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene (2010) 1.36
The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene (2010) 1.32
The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. Annu Rev Pharmacol Toxicol (2011) 1.26
Differential changes in GPR55 during microglial cell activation. FEBS Lett (2009) 1.24
Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther (2010) 1.24
ERK-MAPK drives lamellipodia protrusion by activating the WAVE2 regulatory complex. Mol Cell (2011) 1.22
Dynamics of beta2-adrenergic receptor-ligand complexes on living cells. Biochemistry (2004) 1.21
A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol (2010) 1.21
GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res (2011) 1.21
Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br J Pharmacol (2010) 1.16
mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci (2008) 1.12
Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem (2011) 1.11
Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol (2010) 1.10
Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists. Bioorg Med Chem (2009) 1.09
Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev (2011) 1.09
The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J Biol Chem (2012) 1.05
Filamin A modulates kinase activation and intracellular trafficking of epidermal growth factor receptors in human melanoma cells. Endocrinology (2009) 1.03
{Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells. J Pharmacol Exp Ther (2010) 1.02
Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br J Pharmacol (2010) 1.02
The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene (2012) 1.00
β-arrestin-dependent actin reorganization: bringing the right players together at the leading edge. Mol Pharmacol (2011) 0.96
Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem (2012) 0.96
Lysophosphatidylinositol signalling: new wine from an old bottle. Biochim Biophys Acta (2012) 0.95
GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr Top Med Chem (2010) 0.88
The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor α protein. Br J Pharmacol (2011) 0.87
Affinity of (+/-)-pindolol, (-)-penbutolol, and (-)-tertatolol for pre- and postsynaptic serotonin 5-HT(1A) receptors in human and rat brain. J Neurochem (2000) 0.86
Cannabinoid receptor activation correlates with the proapoptotic action of the β2-adrenergic agonist (R,R')-4-methoxy-1-naphthylfenoterol in HepG2 hepatocarcinoma cells. J Pharmacol Exp Ther (2012) 0.83
Involvement of CB1-receptors and beta-adrenoceptors in the regional hemodynamic responses to lipopolysaccharide infusion in conscious rats. Am J Physiol Heart Circ Physiol (2004) 0.82
Synthesis of bivalent beta2-adrenergic and adenosine A1 receptor ligands. J Med Chem (2008) 0.81
Differential regulation of transcription factors by location-specific EGF receptor signaling via a spatio-temporal interplay of ERK activation. PLoS One (2012) 0.81
[Membrane cholesterol mediates the endocannabinoids-anandamide affection on HepG2 cells]. Zhonghua Gan Zang Bing Za Zhi (2010) 0.80
Functional interactions between the oxytocin receptor and the β2-adrenergic receptor: implications for ERK1/2 activation in human myometrial cells. Cell Signal (2011) 0.80
Pharmacologic characterization of beta blockers with special reference to the significance of nonspecific membrane effects. Am J Cardiol (1991) 0.79
CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol (1985) 0.78
Study on the pharmacological actions of beta-adrenoceptor blockers with reference to their physico-chemical properties. J Pharmacobiodyn (1980) 0.77